news
FDA drafts guidance on post-approval manufacturing for biologics
The FDA has released a draft guidance in response to an increase in the number of post-approval manufacturing supplements...
List view / Grid view
Biologics
news
BIOCAD does its sums for growth
Russian biotech company BIOCAD plans to leverage competitive advantages to take 5% of the European medicines market
news
Lonza Pharma&Biotech Launches Ibex™ Solutions – An Innovative New Concept in Biological Manufacturing and Development
Lonza’s commitment to constant innovation and adding value to its customers and partners is today demonstrated by the launch of Ibex™ Solutions – a unique addition to its current offering...
news
EU approval for Regeneron and Sanofi’s rheumatoid arthritis drug
The European Commission (EC) has granted marketing authorisation for Regeneron and Sanofi’s Kevzara (sarilumab) for the treatment of rheumatoid arthritis...
news
FDA approves BioMarin’s manufacturing facility in Cork, Ireland
The FDA has approved BioMarin Pharmaceutical’s bulk biologics manufacturing plant, located in Cork, Ireland for production of the formulated bulk substance.
news
Leading European health start ups join forces to better serve insurers
Insurance companies are increasingly embracing innovative mobile solutions with the aim of helping their members live healthier lives and access quality care conveniently and efficiently.
news
Asia-Pacific asthma market will hit $6 billion by 2023
The Asia-Pacific (APAC) asthma therapeutics market is expected to grow significantly from $4.1 billion in 2016 to around $6 billion by 2023...
news
Biologics before triple therapy not cost effective for rheumatoid arthritis
30 May 2017 | By American College of Physicians
Stepping up to biologic therapy offers minimal incremental benefit over using a combination of drugs known as triple therapy, yet incurs large costs...
article
Pharma Digitalisation: Challenges and opportunities in transforming the pharma industry
30 May 2017 | By Pasi Kemppainen, Executive Consultant, Pharma Digitalisation and Sammeli Liikkanen, Chief Digital Officer, Orion Pharma
Pharma Digitalisation Executive Consultant, Pasi Kemppainen, and Orion’s CDO Sammeli Liikkanen talk technologies, challenges and opportunities with the digitalisation of pharma…
article
Why biosimilars are changing the pharmaceutical industry
26 May 2017 | By Ho-ung Kim, Head of Strategy and Operations Division for Celltrion Healthcare
We caught up with Celltrion Healthcare's Ho-ung Kim to find out how biosimilars cut costs, increase access to medicine and are ultimately changing the industry…
news
Bioreactors and Fermenters market to reach US $4461 million by 2024
The global Bioreactors and Fermenters Market features a largely consolidated vendor landscape and a low to moderate level of competition, says a new report...
article
Issue #2 2017 – Digital version
Read the free-to-view digital version of the latest issue of European Pharmaceutical Review...
article
Mass Spectrometry In-Depth Focus 2017
In this Mass Spectrometry In-Depth Focus: Mass spectrometry in the development of protein biologics; and GC-MS applications in pharmaceuticals analysis...
webinar
Rethinking Collaboration in Biologics Discovery
4 April 2017 | By Dassault Systèmes BIOVIA
In this webinar, Anne Goupil-Lamy, Ph.D. from BIOVIA demonstrated, using a case study, the value of bringing real time data together during the project: genomics data, predictive models, and experimental assay data...
article
The British Pharmacopoeia – in 2017 and beyond
The British Pharmacopoeia (BP) is a collection of authoritative and publicly available quality standards for medicines, supported by guidance and additional value-adding information. First published in 1864, the BP has an illustrious history that has been built on quality and continually responds to the needs of stakeholders and users.
